And of course, none of this would have been possible without the input from a hugely collaborative, interstate clinical team and the support of many scientists and clinicians @thedohertyinst.bsky.social
We find that an array of inflammatory biomarkers (including cytokines, agalactosylated IgG, and atypical B cells) are elevated in solid tumor patients. These biomarkers negatively correlate with neutralizing antibody responses, but not with antibodies against conserved epitopes or with Fc functions.
In contrast, two COVID-19 mRNA vaccine doses induced robust Fc effector functions, such as antibody-dependent phagocytosis and cytotoxicity, in solid tumor malignancy patients.
SARS-CoV-2 neutralizing antibody responses were significantly lower and less cross-reactive in two-dose mRNA vaccinated solid tumor patients as compared to age-matched controls. A third mRNA vaccination was required to boost neutralizing responses to comparable levels in patients and controls.
Our paper exploring the effects of solid tumor malignancy-associated inflammation upon COVID-19 vaccine-induced antibodies is finally live! We show that while dysregulated inflammation impairs neutralization, variant cross-reactive Fc effector functions remain robust.
Happy to have the latest @amywchung.bsky.social lab preprint online! 🦠 Here we demonstrated that systemic inflammation in solid tumor malignancy patients was associated with impaired SARS-CoV-2 neutralizing antibody functions while non-neutralizing functions remained robust (yay Fc functions!) 🦠
1/ Hot off the press in @jimmunol.bsky.social. We investigated how same side (ipsilateral) vs alternate side (contralateral) prime-boost vaccination impacts germinal center (GC) dynamics & antibody responses against SARS-CoV-2 spike in mice.💉🦠#immunology #vaccines@thedohertyinst.bsky.social
I know everyone missed thinking about IgG4, but we have a new study that finds some very interesting properties of anti-spike IgG4 elicited by mRNA vaccines
tl;dr- IgG4 seems to buffer inflammation but enhances the function of other antibodies when titers are lower
